AURA: Aura Biosciences, Inc. Book Value per Share

Graphic logo of Aura Biosciences Inc (AURA)

This daily price chart for Aura Biosciences, Inc. (AURA) illustrates the asset's quotes, with the current value standing at 3.07. Aura Biosciences, Inc. (AURA) enjoys recognition within the scientific community for developing targeted therapies for bladder and eye tumors. The business relies on unique VDC-conjugates that enable the removal of neoplasms using light without causing vision loss. Innovative virus-like molecules precisely destroy pathologies while preserving the body's healthy cells.

AURA (Aura Biosciences Inc) Accounting Value per Share history from 07/04/2022 to 11/01/2026

Financial and market metric breakdowns for aurabiosciences.com (AURA)

- current quotes and average value forecast:
Price Chart Aura Bio|AURA - Fair Value Consensus
- market capitalization information:
Market Capitalization Aura Biosciences, Inc.|AURA - Enterprise Value
- business book valuation details:
Book Value per Share Aura Biosciences|AURA - Company Net Assets|Market Capitalization to Book Value Ratio aurabiosciences.com|AURA - Company Total Assets
- debt level and financial liquidity data:
Debt to Equity Aura Biosciences, Inc.|AURA - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital Aura Biosciences|AURA - Company Total Debt|Debts to Book Capitalization Aura Biosciences, Inc.|AURA - Long-Term Debt|Company Short-Term Debt Aura Biosciences|Quick Liquidity Indicator aurabiosciences.com
- net income and valuation multiples indicators:
AURA - Final Profit
Initial company analysis:Aura Bio (AURA)
Mass-produced product of aurabiosciences.com

The efficiency of specialized logistics and the preservation of Aura Biosciences, Inc. (AURA) drugs directly impact the company's tangible asset value. By analyzing the book value per common share, an investor assesses the remaining equity after deducting all liabilities, which allows for the determination of the security's real intrinsic value and protects investments from systemic business degradation during market volatility.

Main competitors

ONC - Net Assets per Single Share|Accounting Value of a Share HALO (Halozyme Corp)|RVMD: Book Value per Share|ascentage.com (AAPG) - Book Value per Share|CGON (CG Oncology) - Book Value per Share|Accounting Value per Share UroGen Pharma Ltd (URGN)|Book Value per Share BCAX|Book Value per Share Personalis Genomics (PSNL)|Net Assets per Single Share Erasca, Inc. ERAS|DCTH: Equity per Share|Y-mAbs Therapeutics, Inc. - Book Value per Share|Candel Therapeutics (CADL) - Accounting Value per Share|ARAY: Book Value per Share|Net Asset Value per Share SELLAS Life Sciences Group (SLS)|Net Assets per Single Share Actuate Therapeutics, Inc.|CTOR: Accounting Value of a Share|Accounting Value per Share HURA (TuHURA Biosciences, Inc.)|TARA (Protara Therapeutics Inc) - Accounting Value of a Share|Book Value per Share FATE (Fate Therapeutics Corp)|WHWK - Accounting Value per Share|TCRX: Accounting Value per Share|CSBR - Book Value per Share|xbiotech.com (XBIT) - Net Assets per Single Share|CEL-SCI - Accounting Value of a Share|OSTX (OS Therapies Inc) - Book Value per Share|Net Asset Value per Share radiopharmtheranostics.com RADX|Book Value per Share ARTV|Book Value per Share adlainortye.com (ANL)|Veru - Accounting Value per Share|Book Value per Share Tempest Therapeutics Inc TPST|XLO - Net Assets per Single Share|Accounting Value of a Share RENB (Renovaro Inc.)|MURA: Book Value per Share|Kairos Pharma (KAPA) - Book Value per Share|Accounting Value per Share OKUR|GDTC: Accounting Value of a Share|Book Value per Share CRIS|Net Assets per Single Share APLM (apollomicsinc.com)|Book Value per Share THAR (Tharimmune, Inc.)|Net Assets per Share Advanced Biomed Inc. (ADVB)|GNPX - Net Assets per Single Share|Net Asset Value per Share Calidi Biotherapeutics|Sunshine Biopharma, Inc. (SBFM) - Net Assets per Single Share|XBIO - Net Assets per Share|SLRX (Salarius Pharmaceuticals) - Book Value per Share|Accounting Value per Share purple-biotech.com (PPBT)|Book Value per Share AONC|Net Assets per Share BeiGene Ltd.|Book Value per Share CKPT (Checkpoint Therapeutics, Inc)|elevationoncology.com (ELEV) - Net Asset Value per Share|ICAD - Net Assets per Single Share|IKNA (Ikena Oncology, Inc.) - Equity per Share|NTBL: Book Value per Share|Accounting Value per Share Viracta Therapeutics, Inc.|MOR (MorphoSys Corp) - Book Value per Share|Net Asset Value per Share NAYA Biosciences Corp NAYA|Net Assets per Single Share Ascentage Pharma Group (AAPGV)